Canaccord Genuity reiterates a 'Buy' on AcelRx Pharmaceuticals (ACRX); Hercules Loan Shores Up Cash for ARX-01 Pivotal Trial Costs

Article Stock Quotes (1) Comments (0)

Canaccord Genuity reiterates a 'Buy' on AcelRx Pharmaceuticals (NASDAQ: ACRX), PT $6.

Canaccord analyst Ritu Baral, says, "Reiterate rating and PT on lead candidate ARX 01’s chance of success in patient--controlled post--operative analgesia. ARX-01 is ACRX’s transmucosal sufentanil-based drug-device combo therapy for patientcontrolled post-operative analgesia. We think ARX-01’s two upcoming Phase 3 trials (one versus placebo and one versus current gold standard IV PCA comparator) will yield positive data in mid-2012. ACRX also has a pipeline of drug-device combination pain relief therapies that are created around the core NanoTab sufentanil formulation."

For more ratings news on AcelRx Pharmaceuticals click here and for the rating history of AcelRx Pharmaceuticals click here.

Shares of AcelRx Pharmaceuticals closed at $4.42 yesterday, with a 52 week range of $2.90-$5.09.

---

Join StreetInsider.com FREE and get immediately alerted when news breaks on your stocks and other market items - JOIN NOW

---

*NEW - Download StreetInsider's FREE iPhone and iPad App - Click Here

---

---

You May Also Be Interested In

• AcelRx Pharma (ACRX) Stock Higher; Sufentanil NanoTab Study Meets Primary Endpoint
• Top-line Data Demonstrate Primary Endpoint Achieved in Final Pivotal Phase 3 Study of Sufentanil NanoTab PCA System For Management of Post-Operative Pain
• Jefferies Raises Numbers on hhgregg (HGG), But Remains on Sidelines

Create E-mail Alert Related Categories

Analyst Comments

Add Your Comment

Name

Subject

Body

Share on Facebook

Verification
can't see the text?
click here to refresh the image.
what's this?